Alzai Health Corp. · TSXV:ALZI
Alzai Health — Investor Presentation (June 2026)
25 slides from Alzai Health's investor presentation, June 2026
Slide 1: Predictive Alzheimer's Risk Screening through the Power of AI
Predictive Alzheimer ’s Risk Screening through the Power of AI ΛLZ ΛI HEALTH CORPORATION | JUNE 2026
Slide 2: Legal Disclaimer
Legal Disclaimer THIS MANAGEMENT PRESENTATION (The "presentation") was prepared as a summary overview only of the current screening solution, the company ’s ability to protect its proprietary AI, the company ’s risk screening tool and the affairs of Alzai Health Corp . (”Alzai Health" or the “Compan
Slide 3: Overview
Overview Meeting the Need to Enable Early Alzheimer ’s Detection, Intervention, and Prevention Research studies on ALZAI demonstrated non - invasive CRITICAL NEED: screening for the risk of being diagnosed with Alzheimer's disease with up to 80 % sensitivity. 1 RISK SCREENING • Prevention: Up to one
Slide 4: Highlights
Highlights Innovative, AI- driven, 100% non - Strong IP: Expert legal counsel invasive, low - cost Alzheimer ’s risk confirms robust intellectual screening at population scale. property. Data - powered uses only pre - Meeting the need, While existing data of routine diagnostics, treatments, and demo
Slide 5: About Our Solution
About Our Solution ALZAI Health has created an innovative non - invasive risk screening solution for Alzheimer ’s Disease. We aim to empower healthcare providers, payors, and clinical trial proponents with accessible, AI - powered Alzheimer's risk assessment, enabling pre - symptomatic identificatio
Slide 6: Disease Overview
Disease Overview • # 1 cause of dementia - Alzheimer ’s accounts for up to 80 % of cases. 1 • Rising prevalence - 7M Americans today; 2 projected 13.8 M by 2060 .3 • Global burden - 50 M people worldwide, expected to reach 152M by 2050 .4 • Deadly impact - 7th leading cause of death in the U.S. ( 20
Slide 7: Economic Impact
Economic Impact Nearly • 12M unpaid caregivers in the U.S., contributing care valued 12 Million at $ 413 B annually . 1 Americans provide unpaid care for people with Alzheimer ’s or other dementias • $ 384 B in 2025 projected dementia - related costs (healthcare, long - term care, hospice); nearly $
Slide 8: Risk Screening: Public Acceptance & Demand
Risk Screening: Public Acceptance & Demand • 91% of Americans would take a test before symptoms appear. 1 • 80 % would proactively request testing, not wait for a doctor. 1 • 83 % of diagnosed individuals would join a clinical trial.2 • $ 8.3 B Alzheimer ’s diagnostics market (2024 ), projected to r
Slide 9: Risk Screening is Critical
Risk Screening is Critical ALZAI technology is designed to enable early detection of patients with Alzheimer ’s disease and at high - risk of developing disease, creating critical opportunities: To make a substantial difference in patient trajectories and outcomes. To avoid many cases of disease thr
Slide 10: The Problem With Current Methodology
The Problem With Current Methodology Early- Stage Alzheimer ’s Disease (AD) remains widely undiagnosed due to the needs of risk screening, delaying intervention and treatment. DIAGNOSIS TREATMENT SCREENING TODAY RELIES ON PHYSICIAN SUSPICION • No systematic screening: early Only Mild AD/MCI* Cognit
Slide 11: The Solution Now Available
The Solution Now Available ALZAI ’s AI - Powered Risk Screening for Alzheimer ’s Disease ALZAI uses existing Electronic Medical Records (EMR) and AI to automatically screen populations, identifying high - risk DIAGNOSIS TREATMENT patients. By providing valuable clinical decision support, ALZAI enab
Slide 12: ALZAI Risk Assessment
ALZAI Risk Assessment • Seamless & scalable: Built on a user - friendly, easily integrated platform for healthcare providers, clinical researchers, and stakeholders. • EMR - ready: Standard integration with electronic medical records. • Actionable insights: Risk stratified by year and quantifiable b
Slide 13: Our Customers, Partners & Stakeholders
Our Customers, Partners & Stakeholders Primary Care Risk - Screening Market Recruitment Pre - Screening for Clinical Trials Population - level Reduces screening Alzheimer ’s failure rates risk- screening dramatically A major cost and time Identifying at - risk bottleneck in Alzheimer ’s individu
Slide 14: Primary Care Risk-Screening Market
Primary Care Risk - Screening Market For Healthcare Providers and Payors Target Users Market & Business Model 30 % Reduction in subjects developing AD with early intervention 1 Regulatory: Moderate Large Health Systems & Institutions burden, 510(k) Clinical Decision Support Tool, ~ 24 - 30 to Slower
Slide 15: ALZAI Primary Care Risk-Screening Impact
ALZAI Primary Care Risk - Screening Impact Among an example 2.8 M population over the age of 60 - 280,000 persons are living with Mild AD or MCI. High - precision risk screening leading to diagnosis and treatment could save over $ 64,000 per patient. Prevention can reduce Alzheimer's Disease cases b
Slide 16: Clinical Risk Screening: Upstream of a Growing Diagnostics Market
Clinical Risk Screening: Upstream of a Growing Diagnostics Market • $ 8.3 B market ( 2024 ), projected to reach $ 15.5 B by 2030 (CAGR 11%). 1 • End - user share ( 2024 ): Academic & research 48 % , Hospitals 32 % , Labs 20 %. 1 • North America: Largest market with 47.6 % share . 1 ALZAI is position
Slide 17: Recruitment for Clinical Trials Market
Recruitment for Clinical Trials Market For Clinical Trial Sponsors, Researchers and Service Companies Addresses a key need in Alzheimer's drug development, optimizing clinical trial efficiency and reduces costs. Target Users Market & Business Model Pharmaceutical Companies Regulatory: No significant
Slide 18: ALZAI Risk-Screening for Clinical Trial Impact
ALZAI Risk - Screening for Clinical Trial Impact Clinical trial sponsors, Clinical Research Organizations (CROs) and service companies High - precision pre - screening for risk may reduce screened subjects by up to 57,634 , cutting the cost by $ 30 - $40 M, by lowering screen failure rates, which ac
Slide 19: Company Status
Company Status Proof - of- Concept is Established; Alzai is Commercial - Ready Advanced Proven Intellectual Market Learning & Data Predictive Property & Readiness & Foundation Accuracy Legal Standing Customization Machine learning on Identifies 80 % of at - risk ALZAI has a strong IP Validated, cust
Slide 20: Intellectual Property
Intellectual Property ALZAI ’s Strong Intellectual Property Foundation ALZAI holds exclusive rights to all ALZAI ’s intellectual property has intellectual property generated been rigorously assessed by top through its research and legal experts, ensuring a strong legal innovation: position: Original
Slide 21: Management & Team
Management & Team Hayim Raclaw Roy Kait Dr. Amir Glik, MD Chairperson, Chief Executive Director, Chief Revenue Officer Director, Chief Medical Officer Officer & Co - founder & Co- founder & Co- founder An experienced founder and executive Over 15 years in startups, finance, and Senior Neurologist at
Slide 22: Management & Team
Management & Team Ofri Kait Jenny Greer Prof. Chen Hajaj Director Business Development Executive Assistant Head of Data Science & Operations A decade of experience in venture A highly accomplished Executive Assistant, Founder of the Data Science and AI creation, business development, with15 years ex
Slide 23: Board of Directors
Board of Directors Hayim Raclaw Roy Kait Dr. Amir Glik, MD Chairperson, Chief Executive Director, Chief Revenue Officer Director, Chief Medical Officer Officer & Co - founder & Co- founder & Co- founder An experienced founder and executive Over 15 years in startups, finance, and Senior Neurologist a
Slide 24: Board of Advisors
Board of Advisors Dr. Michael Greenberg, MD Prof. Lindsay A. Farrer, Ph.D. Neurosurgeon, Entrepreneur, PubCo Leading NIH - funded programs, CEO, Experienced company developer identified causal factors for AD Med- Tech CEO who led a medical imaging Chief of Biomedical Genetics at Boston company to NA
Slide 25: Thank You
Thank You Predictive ΛLZ ΛI Health Corp. Alzheimer ’s Risk 22 Adelaide St W # 3400 , Screening through Toronto, ON M 5H 4E3, Canada Phone: + 1 (416) 862 4351 the Power of AI info@alzaihealth.com www.alzaihealth.com ΛLZ ΛI HEALTH CORPORATION | JUNE 2026